Product Data Sheet

MAGL-IN-9

Molecular Weight: 490.51
Target: MAGL

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	MAGL-IN-9 (compound 16) is a selective and reversible MAGL inhibitor with IC $_{50}$ 2.7 nM $^{[1]}$.
IC ₅₀ & Target	IC50: 2.7 nM (MAGL) ^[1]
In Vitro	MAGL-IN-9 (10 μ M, 25 min) selectively inhibits MAGL in mouse brain membrane preparations, without affecting other serine hydrolases such as FAAH, ABHD6, and ABHD12 ^[1] . MAGL-IN-9 shows a reversible inhibition mechanism in both preincubation and dilution tests ^[1] . MAGL-IN-9 inhibits MAGL in U973 cells with an IC ₅₀ value of 193 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Di Stefano M, et al. Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors[J]. European Journal of Medicinal Chemistry, 2023: 115916.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA